NCT07222280 Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
| NCT ID | NCT07222280 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Covenant Health, US |
| Condition | Alzheimer Dementia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-06-10 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-06-10 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Eligibility Criteria
Inclusion Criteria: * Ages 60 to 90 years old * No prior diagnosis of dementia * Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state Exclusion Criteria: * Age under 60 years * Prior diagnosis of dementing illness or other organic etiology to cognitive impairment
Contact & Investigator
Samuel Moore, MD
PRINCIPAL INVESTIGATOR
Covenant Health, Canada
Frequently Asked Questions
Who can join the NCT07222280 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 90 Years, studying Alzheimer Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07222280 currently recruiting?
Yes, NCT07222280 is actively recruiting participants. Contact the research team at aholt10@covhlth.com for enrollment information.
Where is the NCT07222280 trial being conducted?
This trial is being conducted at Crossville, United States, Harriman, United States, Knoxville, United States, Lenoir City, United States and 2 additional locations.
Who is sponsoring the NCT07222280 clinical trial?
NCT07222280 is sponsored by Covenant Health, US. The principal investigator is Samuel Moore, MD at Covenant Health, Canada. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.